| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Animal studies in rodent and equine models for wound healing, cardiac repair, and tissue regeneration. Some equine veterinary use. No human RCTs published. Animal only. |
5 / 25 |
| Sample Size | No human efficacy participants. Animal cohorts typically small. |
4 / 20 |
| Replication | Thymosin beta-4 (the parent molecule) research replicated across multiple academic groups — RegeneRx Pharmaceuticals, NIH-funded labs, and independent university groups. TB-500 as synthetic fragment benefits from thymosin beta-4 literature. |
10 / 20 |
| Journal Impact Factor | Thymosin beta-4 publications include papers in PNAS (IF ~11), Annals of the New York Academy of Sciences, and Journal of Cell Biology. Parent molecule has strong journal placement. |
8 / 15 |
| Funding Independence | NIH-funded academic work on thymosin beta-4 is substantial. RegeneRx Pharmaceuticals (developer) has some involvement but meaningful independent academic base. |
7 / 10 |
| Population Diversity | Animal only. Not applicable. |
5 / 5 |
| Researcher h-Index | Hynda Kleinman (NIH) and Allan Goldstein (GWU) — both prominent researchers with h-Indexes 40+. TB-500/thymosin beta-4 has serious researchers behind it. Capped at 5. |
2 / 5 |